<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00582582</url>
  </required_header>
  <id_info>
    <org_study_id>HSC 2001-484</org_study_id>
    <secondary_id>CO01802</secondary_id>
    <nct_id>NCT00582582</nct_id>
  </id_info>
  <brief_title>Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer</brief_title>
  <official_title>Phase II Evaluation of Docetaxel Randomized With Doxercalciferol or Placebo in Patients With Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find out the toxicities of doxercalciferol given in&#xD;
      combination with docetaxel (TaxotereÂ®), as well as to see how well this combination works in&#xD;
      the treatment of prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-institutional, double-blinded, randomized study comparing docetaxel plus&#xD;
      doxercalciferol versus docetaxel plus placebo in patients with metastatic hormone refractory&#xD;
      prostate cancer. Docetaxel is given intravenously on days 1, 8 and 15 for every 28 day cycle&#xD;
      and doxercalciferol or placebo is taken orally every day of the 28 day cycle. Please refer to&#xD;
      the Eligibility Criteria below for key inclusion and exclusion criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of drug supply for doxercalciferol for this study&#xD;
  </why_stopped>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>At 12 weeks on study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Duration of study participation through 30 days post last treatment dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel plus doxercalciferol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Docetaxel plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel plus doxercalciferol</intervention_name>
    <description>Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Taxotere</other_name>
    <other_name>Hectoral</other_name>
    <other_name>1a,hydroxyvitamin D2</other_name>
    <other_name>1a-OH-D2</other_name>
    <other_name>1a-hydroxyerocalciferol</other_name>
    <other_name>Vitamin D analog</other_name>
    <other_name>prodrug of 1a,25-dihydroxyvitamin D2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel plus placebo</intervention_name>
    <description>Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of adenocarcinoma of the prostate.&#xD;
&#xD;
          -  evidence of metastatic disease within 4 weeks of registration.&#xD;
&#xD;
          -  Must meet ONE of the following:&#xD;
&#xD;
               1. PSA &gt;or= 10 ng/mL and at least one lesion on bone scan.&#xD;
&#xD;
               2. Soft tissue metastases and/or visceral disease per CT scan.&#xD;
&#xD;
          -  Must show progressing prostate cancer as seen by one of the following:&#xD;
&#xD;
               1. At least one new lesion on bone scan,&#xD;
&#xD;
               2. Increase in size or number of measurable disease lesions,&#xD;
&#xD;
               3. At least 2 rising PSA measurements at least two weeks apart.&#xD;
&#xD;
          -  Prior bilateral orchiectomy or on LHRH agonist therapy with a serum testosterone level&#xD;
             of &lt; 50.&#xD;
&#xD;
          -  Must be off flutamide, nilutamide, or ketoconazole or herbal supplements used to treat&#xD;
             prostate cancer at least 4 weeks prior to registration and bicalutamide at least 6&#xD;
             weeks prior to registration.&#xD;
&#xD;
          -  No prior cytotoxic chemotherapy.&#xD;
&#xD;
          -  WHO performance status of 0-2.&#xD;
&#xD;
          -  Peripheral neuropathy must be &lt; or = to grade 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of a radiographically confirmed kidney stone or pathologically confirmed&#xD;
             calcium stone within the last 10 years.&#xD;
&#xD;
          -  Patients can continue to take bisphosphonates during the study as long as the&#xD;
             bisphosphonate was started at least 4 weeks prior to study entry and the patient&#xD;
             continues to demonstrate a rising PSA&#xD;
&#xD;
          -  No prior treatment with suramin, strontium or other therapeutic radioisotopes.&#xD;
&#xD;
          -  No radiotherapy within the past 4 weeks.&#xD;
&#xD;
          -  No known brain metastases.&#xD;
&#xD;
          -  No chronic hypercalcemia (serum calcium &gt;1.0 mg/dl above the upper limit of normal&#xD;
             range), chronic gastrointestinal disease (malabsorption, surgery affecting absorption,&#xD;
             chronic ulcerative colitis) or any condition that the investigator feels would put the&#xD;
             patient at undue risk.&#xD;
&#xD;
          -  Must not be taking digitalis, thiazide diuretics (or drugs in combination with&#xD;
             thiazides) or calcium supplements within one week of treatment initiation.&#xD;
&#xD;
          -  No active angina, known heart disease of New York Heart Association Class II-IV or a&#xD;
             recent history (&lt; 6 months) of myocardial infarction.&#xD;
&#xD;
          -  Must not be taking steroids, anticonvulsants, fluoride, or lithium.&#xD;
&#xD;
          -  Must not have urinary protein &gt; 4gm/24 hours&#xD;
&#xD;
          -  Must not have urinary calcium &gt; or= 500 mg/24 hours&#xD;
&#xD;
          -  No Coexistent second malignancy or history of prior malignancy within previous 5 years&#xD;
             (excluding basal or squamous cell carcinoma of the skin that has been treated&#xD;
             curatively).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Wilding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-5669</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2007</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Hormone Refractory</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Dihydroxycholecalciferols</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

